1832 Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

1832 Asset Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,050	Closed	-$272K	–	785
2021 Q3	$272K	Sell	13,050 -81,950	-86%	-$1.75M	﹤0.01%	632
2021 Q2	$2.02M	Sell	95,000 -208,800	-69%	-$4.22M	﹤0.01%	424
2021 Q1	$5.94M	Sell	303,800 -139,296	-31%	-$2.87M	0.01%	346
2020 Q4	$8.8M	Buy	443,096 +8,696	+2%	+$161K	0.02%	297
2020 Q3	$7.67M	Hold	434,400	–	–	0.02%	283
2020 Q2	$7.72M	Buy	434,400 +149,400	+52%	+$2.56M	0.02%	257
2020 Q1	$4.31M	Buy	285,000 +159,066	+126%	+$2.6M	0.02%	310
2019 Q4	$2.2M	Buy	125,934 +45,934	+57%	+$754K	0.01%	378
2019 Q3	$1.21M	Hold	80,000	–	–	﹤0.01%	419
2019 Q2	$1.33M	Buy	+80,000	New	+$1.32M	﹤0.01%	446

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

1832 Asset Management's HQL Position: Q4 2021 in Review

1832 Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q4 2021, closing a stake of 13,050 shares — an estimated $272K sold.

1832 Asset Management first reported a position in HQL in Q2 2019 and held it in 10 quarters. The position peaked at $8.8M in Q4 2020. 67 funds tracked by Wall St. Rank hold HQL as of Q4 2021.

1832 Asset Management reported no remaining abrdn Life Sciences Investors position as of Q4 2021 after selling out during the quarter.
1832 Asset Management sold 13,050 abrdn Life Sciences Investors shares in Q4 2021, an estimated $272K.
1832 Asset Management first reported a position in abrdn Life Sciences Investors in Q2 2019 and held it in 10 quarters.
1832 Asset Management's abrdn Life Sciences Investors position peaked at $8.8M in Q4 2020.
67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2021.

Based on 1832 Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.